Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
1915
5.7K+
LTM Revenue n/a
LTM EBITDA n/a
$7.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lundbeck has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Lundbeck achieved revenue of $3.1B and an EBITDA of $797M.
Lundbeck expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Lundbeck valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $2.5B | $2.8B | $3.1B | n/a | XXX |
Gross Profit | $2.0B | $2.2B | $2.5B | XXX | XXX |
Gross Margin | 78% | 77% | 81% | XXX | XXX |
EBITDA | $613M | $707M | $797M | n/a | XXX |
EBITDA Margin | 24% | 25% | 26% | NaN% | XXX |
Net Profit | $268M | $320M | $439M | XXX | XXX |
Net Margin | 11% | 12% | 14% | XXX | XXX |
Net Debt | $234M | n/a | $1.6B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Lundbeck's stock price is DKK 41 (or $6).
Lundbeck has current market cap of DKK 40.3B (or $5.6B), and EV of DKK 52.3B (or $7.3B).
See Lundbeck trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$7.3B | $5.6B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Lundbeck has market cap of $5.6B and EV of $7.3B.
Lundbeck's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Lundbeck's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Lundbeck and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $7.3B | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLundbeck's NTM/LTM revenue growth is n/a
Lundbeck's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Lundbeck's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Lundbeck's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Lundbeck and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 11% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
Opex to Revenue | 66% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lundbeck acquired XXX companies to date.
Last acquisition by Lundbeck was XXXXXXXX, XXXXX XXXXX XXXXXX . Lundbeck acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Lundbeck founded? | Lundbeck was founded in 1915. |
Where is Lundbeck headquartered? | Lundbeck is headquartered in Denmark. |
How many employees does Lundbeck have? | As of today, Lundbeck has 5.7K+ employees. |
Is Lundbeck publicy listed? | Yes, Lundbeck is a public company listed on CSE. |
What is the stock symbol of Lundbeck? | Lundbeck trades under HLUN A ticker. |
When did Lundbeck go public? | Lundbeck went public in 2022. |
Who are competitors of Lundbeck? | Similar companies to Lundbeck include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of Lundbeck? | Lundbeck's current market cap is $5.6B |
What is the current revenue growth of Lundbeck? | Lundbeck revenue growth between 2023 and 2024 was 11%. |
Is Lundbeck profitable? | Yes, Lundbeck is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.